

Registered Office:

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GICD - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451



Date: January 28, 2025

To,
The Manager,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block – G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Dear Sir/ Ma'am,

Sub: Outcome of board meeting held today i.e. on, Tuesday, January 28, 2025, in terms of second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held today, i.e. on Tuesday, January 28, 2025 at the Registered Office of the Company situated at PF-21, Nr. Acme Pharma, Opp. Teva Pharma, Sanand GICD-II, Sanand, Ahmedabad- 382110, Gujarat, which was commenced at 04:45 P.M. and concluded at 05:15 P.M., to have;

1. On Recommendation of Nomination & Remuneration Committee Considered and Approved appointment of Mr. Pankaj Prabhakar Mahabaleshwarkar as a Chief Operating Officer (“COO”) of the Company.

Necessary Disclosures pursuant to SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 for the appointment of Chief Operating Officer (“COO”) of the Company under Regulation 30 of the SEBI (LODR) Regulations, 2015 is enclosed herewith as “Annexure A”.

2. Considered and approved all other business as per agenda circulated.

Kindly take the same on your record and oblige us.

Thanking you.

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

Encl: - A/a

Registered Office:

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GICD - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451



“ANNEXURE A”

Details as required under Regulation 30 read with Schedule III of The SEBI (LODR) Regulations, 2015 and in terms of SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023:

Sr No	Particulars	Details of COO
1	Name	Mr. Pankaj Prabhakar Mahabaleshwarkar
2	Reason for change viz. appointment, re-appointment, Resignation, removal, death or otherwise	Appointment as Chief Operating Officer (“COO”)
3	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/ re-appointment	Date of appointment: January 28, 2025 Term of appointment: full time employment
4	Brief profile (in case of appointment);	<p>Mr. Pankaj Prabhakar Mahabaleshwarkar is a results-driven leader with 30+ years of experience in leading world-class formulation facilities, driving operational excellence, quality, and regulatory compliance.</p> <p>He combines integrity, foresight, and leadership expertise with a strong track record in managing manufacturing units, regulatory affairs, and budget planning. His expertise spans production budgeting, resource optimization, and balancing operational efficiency with quality. With extensive experience in USFDA, MHRA, and other regulatory audits, He is well-positioned to drive business growth while ensuring global regulatory compliance.</p> <p>Before joining Sotac, he was associated with Intas Pharma Limited as Associate Ex. Vice President Manufacturing Operations and leading the Manufacturing site. Amongst others, he has also worked in pharma companies like Zydus Lifesciences Limited, Hospira Healthcare India Private Limited, Zydus Hospira Oncology Private Limited, Strides Arcolab Limited and Sigma Labs Limited.</p>
5	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable
6	Declaration - Circulars NSE / CML / 2018 / 24 and LIST / COMP / 14 / 2018 - 19 dated June 20, 2018	Not Applicable

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad